Pharmacometrics Golems: Exposure‐Response Models in Oncology

This publication has 9 references indexed in Scilit:

• Statistical Rethinking
  2020
• Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
  CPT: Pharmacometrics & Systems Pharmacology, 2020
• Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
  Lung Cancer, 2018
• Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
  Clinical Pharmacology & Therapeutics, 2017
• Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions
  Clinical Cancer Research, 2017
• Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
  Clinical and Experimental Gastroenterology, 2012
• Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31
  Journal of Clinical Oncology, 2009
• Sufficient conditions for treatment responders to have longer survival than non-responders
  Statistics & Probability Letters, 1993
• Analysis of survival by tumor response.
  Journal of Clinical Oncology, 1983